Natasha Khrystolubova is one of the lead author of the Journal of Oncology Pharmacy Practice article, Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting.
An NCODA practice working to make a difference in the pharmacy to positively impact patient care. Florida Cancer Specialists (FCL) have taken an active role in patient care and adherence.
Going Beyond the First Fill gives every patient the monitoring and follow-up to improve care at the pharmacy level through best practices. These are challenges real community-based pharmacies are facing. FCS gives patients the support needed through health education and resources. “The FCS program was designed specifically to manage AEs that occurred during use of afatinib, but many of the principles and approaches could be implemented for patients treated with other types of medication. ” Read More.
Chemotherapy once meant:
- An extended series of visits to a treatment center,
- Where the patient would be hooked up to an IV, often for hours, and infused with a heavy dose of anticancer drugs and supportive care medicines,
- All while being constantly monitored by healthcare professionals.
Nowadays, that same process often can be accomplished by simply sending the patient home with a bottle of pills. Read More Here.
Although oral chemotherapy has dramatically changed the face of cancer treatment, how the drugs are dispensed can be nearly as important as the drugs themselves.
“It’s one thing to prescribe an oral medicine for a patient,” said Guri K. Doshi, MD, a urinary and prostate cancer specialist with Texas Oncology, the state’s largest cancer care provider. “It’s another to get it into their hands.” Read more here.
Chris Kepinski speaking at AJMC’s Institute for Value-Based Medicine
NCODA member Chris Kepinski, clinical oncology pharmacy manager for Southern Oncology Specialists in North Carolina, recently spoke on a national panel regarding advancing quality in oncology care as part of the Institute for Value-Based Medicine, a new initiative of The American Journal of Managed Care.
Read entire article in AJMC Here
The addition of abemaciclib (Verzenio) to initial treatment with a nonsteroidal aromatase inhibitor appeared effective for women with hormone receptor-positive, HER-2-negative advanced breast cancer, according to results of the double-blind, phase 3 MONARCH 3 study presented at American Association for Cancer Research Annual Meeting.
Read More Here